Detalhe da pesquisa
1.
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
Ann Oncol
; 35(5): 414-428, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38431043
2.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ann Oncol
; 35(3): 248-266, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307807
3.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Br J Cancer
; 128(8): 1503-1513, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36759720
4.
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Ann Oncol
; 34(12): 1152-1164, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797734
5.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ann Oncol
; 34(8): 681-692, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37211045
6.
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Ann Oncol
; 33(10): 1021-1028, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772665
7.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Ann Oncol
; 33(6): 593-601, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219776
8.
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
Ann Oncol
; 33(3): 276-287, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861371
9.
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Gynecol Oncol
; 164(3): 498-504, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35063276
10.
The systemic treatment of recurrent ovarian cancer revisited.
Ann Oncol
; 32(6): 710-725, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33675937
11.
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Ann Oncol
; 32(6): 757-765, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667670
12.
Cervical re-injection of indocyanine green to improve sentinel lymph node detection in endometrial cancer.
Gynecol Oncol
; 162(1): 38-42, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906784
13.
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Ann Oncol
; 31(9): 1148-1159, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32569725
14.
Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
Gynecol Oncol
; 157(1): 85-88, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31954531
15.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Ann Oncol
; 30(5): 672-705, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046081
16.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Ann Oncol
; 30(7): 1080-1087, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046082
17.
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Gynecol Oncol
; 155(3): 406-412, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31677820
18.
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
Gynecol Oncol
; 152(2): 235-242, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30466805
19.
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Gynecol Oncol
; 155(2): 186-191, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31519320
20.
Prokaryotic Diversity and Distribution in Different Habitats of an Alpine Rock Glacier-Pond System.
Microb Ecol
; 78(1): 70-84, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30317429